Telavancin and daptomycin activity against meticillin-resistant Staphylococcus aureus strains after vancomycin-resistance selection in vitro

References

1. Cui L., Ma X., Sato K., Okuma K., Tenover F. C., Mamizuka E. M., Gemmell C. G., Kim M. N., Ploy M. C. et al. 2003; Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 41:5–14 [View Article][PubMed]
   [Google Scholar]
2. Cui L., Lian J. Q., Neoh H. M., Reyes E., Hiramatsu K. 2005; DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother 49:3404–3413 [View Article][PubMed]
   [Google Scholar]
3. Draghi D. C., Benton B. M., Krause K. M., Thornsberry C., Pillar C., Sahm D. F. 2008; Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother 52:2383–2388 [View Article][PubMed]
   [Google Scholar]
4. Gander S., Kinnaird A., Finch R. 2005; Telavancin: in vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother 56:337–343 [View Article][PubMed]
   [Google Scholar]
5. Hobbs J. K., Miller K., O’Neill A. J., Chopra I. 2008; Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother 62:1003–1008 [View Article][PubMed]
   [Google Scholar]
6. Jones R. N. 2006; Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 42:Suppl 1S13–S24 [View Article][PubMed]
   [Google Scholar]
7. Jung D., Rozek A., Okon M., Hancock R. E. 2004; Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol 11:949–957 [View Article][PubMed]
   [Google Scholar]
8. Kanafani Z. A. 2006; Telavancin: a new lipoglycopeptide with multiple mechanisms of action. Expert Rev Anti Infect Ther 4:743–749 [View Article][PubMed]
   [Google Scholar]
9. Leuthner K. D., Cheung C. M., Rybak M. J. 2006; Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 58:338–343 [View Article][PubMed]
   [Google Scholar]
10. Liu C., Bayer A., Cosgrove S. E., Daum R. S., Fridkin S. K., Gorwitz R. J., Kaplan S. L., Karchmer A. W., Levine D. P. et al. 2011; Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52:e18–e55 [View Article][PubMed]
    [Google Scholar]
11. Moubareck C., Meziane-Cherif D., Courvalin P., Périchon B. 2009; VanA-type Staphylococcus aureus strain VRSA-7 is partially dependent on vancomycin for growth. Antimicrob Agents Chemother 53:3657–3663 [View Article][PubMed]
    [Google Scholar]
12. Neoh H. M., Hori S., Komatsu M., Oguri T., Takeuchi F., Cui L., Hiramatsu K. 2007; Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann Clin Microbiol Antimicrob 6:13 [View Article][PubMed]
    [Google Scholar]
13. Pace J. L., Krause K., Johnston D., Debabov D., Wu T., Farrington L., Lane C., Higgins D. L., Christensen B. et al. 2003; In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 47:3602–3604 [View Article][PubMed]
    [Google Scholar]
14. Peleg A. Y., Miyakis S., Ward D. V., Earl A. M., Rubio A., Cameron D. R., Pillai S., Moellering R. C. Jr, Eliopoulos G. M. 2012; Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS ONE 7:e28316 [View Article][PubMed]
    [Google Scholar]
15. Petrosillo N., Capone A., Di Bella S., Taglietti F. 2010; Management of antibiotic resistance in the intensive care unit setting. Expert Rev Anti Infect Ther 8:289–302 [View Article][PubMed]
    [Google Scholar]
16. Sakoulas G., Moise-Broder P. A., Schentag J., Forrest A., Moellering R. C. Jr, Eliopoulos G. M. 2004; Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398–2402 [View Article][PubMed]
    [Google Scholar]
17. van Hal S. J., Paterson D. L., Gosbell I. B. 2011; Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient–a review of the literature. Eur J Clin Microbiol Infect Dis 30:603–610 [View Article][PubMed]
    [Google Scholar]